GLP-1/glucagonInvestigational · Phase 3

Survodutide

Last updated

Dual glucagon and GLP-1 receptor agonist. Once weekly.

Survodutide (investigational)·Boehringer Ingelheim / Zealand Pharma

Other GLP-1 medicines at sellers we link to

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

No seller we link to sells survodutide; these are different medicines, compounded and not FDA-approved. Those sellers pay us if you buy, which never changes a price we show.

Catalog reviewed Nov 4, 2026. Feed checks and price reviews are dated separately below. How we verify. Not medical advice.

Data updated . What changed

Average weight lost in its trials

  • 6.0 mg weekly (Phase 3)SYNCHRONIZE-1 (Phase 3) · 76 wks
    −16.6% (nejm.org/doi/full/10.1056/NEJMoa2600751) (-16.6% at 76 wks · SYNCHRONIZE-1 (Phase 3) · 6.0 mg weekly (Phase 3))about 33 lb at 200 lb

Averages from separate trials, so they are not a head-to-head ranking and not a prediction. Pounds apply the percentage to a 200 lb starting weight.

Investigational: not FDA-approved for this or any use. It is still being studied in trials.

Information from FDA labels and published trials, not medical advice.

What to know about Survodutide

An ingredient can have several brands, formulations, and approved uses. Prices and trial findings belong to the specific product and dose shown.

Mean weight change in the cited trial
−16.6% (nejm.org/doi/full/10.1056/NEJMoa2600751) (-16.6% at 76 wks · SYNCHRONIZE-1 (Phase 3) · 6.0 mg weekly (Phase 3))

SYNCHRONIZE-1 (Phase 3) · 6.0 mg weekly (Phase 3)

A1c reduction in the cited trial
−0.8 pp (nejm.org/doi/full/10.1056/NEJMoa2607219) (-0.8 percentage points at 76 wks (6.0 mg; SYNCHRONIZE-2, type 2 diabetes) · SYNCHRONIZE-2 (Phase 3 T2D) · HbA1c change in percentage points)

SYNCHRONIZE-2 (Phase 3 T2D)

Stopped treatment for adverse events
24.8% (nejm.org/doi/full/10.1056/NEJMoa2600751) (24.8% vs 5.4% placebo (6.0 mg) · SYNCHRONIZE-1 (6.0 mg, 76 wks, obesity))

SYNCHRONIZE-1 (6.0 mg, 76 wks, obesity)

FDA shortage report
In development

Investigational. Not FDA-approved.

Route & frequency
Once weekly

Trial averages are not personal predictions. Weight-loss, A1c, and side-effect figures may come from different trials, doses, or populations; follow each source for its context.

How to read the trial results
  • In adults with obesity and type 2 diabetes (SYNCHRONIZE-2, 752 people, 76 wks), weight fell -9.8% at 6.0 mg and -8.2% at 3.6 mg vs -3.9% placebo on the treatment-regimen estimand, and A1c fell 0.8 and 0.9 percentage points vs 0.2 from a 7.4% baseline. Gastrointestinal events affected 77.7% at 6.0 mg vs 38.6% on placebo. SYNCHRONIZE-2 (NEJM, Oct 2026) (nejm.org)
Indications

Investigational uses

Survodutide (investigational)

Obesity; MASH (investigational)

An investigational dual glucagon/GLP-1 receptor agonist; the glucagon component is being studied for effects on liver fat and metabolism.

Product labeling

Dosing, warnings & contraindications

Choose the named product and route. These are submitted label records, which may differ from current approved prescribing information. The product links above lead to current prescribing information. Indexed text omits tables and images; always read the full source label.

No approved label (investigational)

Survodutide is investigational. See its registered studies below. Search DailyMed (dailymed.nlm.nih.gov).

Source: submitted product labeling via openFDA. A listing does not establish FDA approval and may differ from current approved labeling. Read the current prescribing information and consult a clinician.
Tolerability

Side effects reported in the trial

Reported adverse events and treatment discontinuation from the cited trial. These figures do not predict an individual response.

Discontinued for side effects

24.8% (nejm.org/doi/full/10.1056/NEJMoa2600751) (24.8% vs 5.4% placebo (6.0 mg) · SYNCHRONIZE-1 (6.0 mg, 76 wks, obesity))

Reported as 24.8% vs 5.4% placebo (6.0 mg). The share of trial participants who stopped treatment because of adverse events. This does not measure all side effects or all reasons for stopping.

Had nausea

64.9% (nejm.org/doi/full/10.1056/NEJMoa2600751) (Nausea in the drug arm · SYNCHRONIZE-1 (6.0 mg, 76 wks, obesity))

The share of participants who reported nausea in this trial. Severity and duration are not captured by this percentage.

GI events (nausea 65%, vomiting 45%, diarrhea 40%) affected 89.7% of the 6.0 mg arm, the highest GI burden of the class, mostly mild-to-moderate and during dose escalation.

From SYNCHRONIZE-1 (6.0 mg, 76 wks, obesity) (the share who stopped survodutide because of adverse events, as reported from the NEJM paper (23.7% at 3.6 mg); Boehringer Ingelheim's own release gives 19% stopping for gastrointestinal adverse events across both doses vs 2.9% on placebo. Gastrointestinal events affected 89.7% of the 6.0 mg group (NEJM abstract)). Tolerability figures come from each drug's own trial (different doses, durations, and populations), so compare them as a guide, not a head-to-head. Source (nejm.org).

Evidence

Clinical trials

27 of 30 registered studies indexed. Showing up to 12 records: posted results first, then late-phase trials. Registry counts are not a measure of evidence quality.

  • A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight (clinicaltrials.gov/study/NCT04667377)
    NCT04667377PHASE2Completed387 enrolled
    Has results
    Primary outcome: Percentage Change in Body Weight From Baseline to Week 46

    Selected primary outcome

    Results · Nov 14, 2026 UTC

    Percentage Change in Body Weight From Baseline to Week 46

    Least-squares mean · Percentage change · Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46.

    Analysis population: Full analysis set (all randomised participants who received at least one dose of study treatment and who have analysable data for at least one efficacy endpoint) using planned maintenance treatment. Number of participants analysed = Participants with available data for the outcome measure.

    0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation)
    -6.19 Percentage change (clinicaltrials.gov/study/NCT04667377)

    Standard Error: 1.07 (clinicaltrials.gov)

    Overall outcome: 76 Participants (clinicaltrials.gov/study/NCT04667377) analyzed

    2.4 mg BI 456906 - Planned Maintenance Treatment
    -12.51 Percentage change (clinicaltrials.gov/study/NCT04667377)

    Standard Error: 1.01 (clinicaltrials.gov)

    Overall outcome: 78 Participants (clinicaltrials.gov/study/NCT04667377) analyzed

    3.6 mg BI 456906 - Planned Maintenance Treatment
    -13.22 Percentage change (clinicaltrials.gov/study/NCT04667377)

    Standard Error: 1.04 (clinicaltrials.gov)

    Overall outcome: 76 Participants (clinicaltrials.gov/study/NCT04667377) analyzed

    4.8 mg BI 456906 - Planned Maintenance Treatment
    -14.94 Percentage change (clinicaltrials.gov/study/NCT04667377)

    Standard Error: 1.01 (clinicaltrials.gov)

    Overall outcome: 76 Participants (clinicaltrials.gov/study/NCT04667377) analyzed

    Placebo
    -2.82 Percentage change (clinicaltrials.gov/study/NCT04667377)

    Standard Error: 1.06 (clinicaltrials.gov)

    Overall outcome: 77 Participants (clinicaltrials.gov/study/NCT04667377) analyzed

    Outcome definition & treatment groups

    Percentage change in body weight from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline body weight as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit (Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures, an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. That is, a hypothetical strategy was used for intercurrent event (ICE) "COVID-19 pandemic-related early treatment discontinuation", a treatment policy strategy for ICE "non-pandemic-related early treatment discontinuation".

    0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation): Participants with obesity or overweight were administered a solution for injection of BI 456906, by a weekly subcutaneous injection of two syringes (0.5 mL filling volume per syringe) on the same injection day, of 0.3 mg on Week 1 and 2, and 0.6 mg on Week 3 to Week 20 (dose escalation phase, with fixed dose escalation from Week 1 to Week 10 and flexible dose escalation from Week 11 to Week 20). From Week 21 to Week 46 (maintenance dosing phase) participants stayed on the dose of 0.6 mg BI 456906. Participant not tolerating the assigned dose escalation schedule due to gastrointestinal adverse events had the option of dose adjustment during the flexible part of the dose escalation phase (Week 11 - 20) which could lead to a maintenance dose lower than the dose the participant was randomised to.

    2.4 mg BI 456906 - Planned Maintenance Treatment: Participants with obesity or overweight were administered a solution for injection of BI 456906, by a weekly subcutaneous injection of two syringes (0.5 mL filling volume per syringe) on the same injection day, of 0.3 mg on Week 1 and Week 2, 0.6 mg on Week 3 and Week 4, 0.9 mg on Week 5 and Week 6, 1.2 mg on Week 7 to Week 10, 1.8 mg on Week 11 to Week 14 and 2.4 mg on Week 15 to Week 20 (dose escalation phase, with fixed dose escalation from Week 1 to Week 10 and flexible dose escalation from Week 11 to Week 20). From Week 21 to Week 46 (maintenance dosing phase) participants stayed on the dose of 2.4 mg BI 456906. Participant not tolerating the assigned dose escalation schedule due to gastrointestinal adverse events had the option of dose adjustment during the flexible part of the dose escalation phase (Week 11 - 20) which could lead to a maintenance dose lower than the dose the participant was randomised to.

    3.6 mg BI 456906 - Planned Maintenance Treatment: Participants with obesity or overweight were administered a solution for injection of BI 456906, by a weekly subcutaneous injection of two syringes (0.5 mL filling volume per syringe) on the same injection day, of 0.3 mg on Week 1 and Week 2, 0.6 mg on Week 3 and Week 4, 0.9 mg on Week 5 and Week 6, 1.2 mg on Week 7 to Week 10, 1.8 mg on Week 11 and Week 12, 2.4 mg on Week 13 and Week 14, 3.0 mg on Week 15 and Week 16, and 3.6 mg on Week 17 to Week 20 (dose escalation phase, with fixed dose escalation from Week 1 to Week 10 and flexible dose escalation from Week 11 to Week 20). From Week 21 to Week 46 (maintenance dosing phase) participants stayed on the dose of 3.6 mg BI 456906. Participant not tolerating the assigned dose escalation schedule due to gastrointestinal adverse events had the option of dose adjustment during the flexible part of the dose escalation phase (Week 11 - 20) which could lead to a maintenance dose lower than the dose the participant was randomised to.

    4.8 mg BI 456906 - Planned Maintenance Treatment: Participants with obesity or overweight were administered a solution for injection of BI 456906, by a weekly subcutaneous injection of two syringes (0.5 mL filling volume per syringe) on the same injection day, of 0.3 mg on Week 1 and Week 2, 0.6 mg on Week 3 and Week 4, 0.9 mg on Week 5 and Week 6, 1.2 mg on Week 7 and Week 8, 1.8 mg on Week 9 and Week 10, 2.4 mg on Week 11 and Week 12, 3.3 mg on Week 13 and Week 14, 4.2 mg on Week 15 and Week 16, and 4.8 mg on Week 17 to Week 20 (dose escalation phase, with fixed dose escalation from Week 1 to Week 10 and flexible dose escalation from Week 11 to Week 20). From Week 21 to Week 46 (maintenance dosing phase) participants stayed on the dose of 4.8 mg BI 456906. Participant not tolerating the assigned dose escalation schedule due to gastrointestinal adverse events had the option of dose adjustment during the flexible part of the dose escalation phase (Week 11 - 20) which could lead to a maintenance dose lower than the dose the participant was randomised to.

    Placebo: Participants with obesity or overweight were administered a solution for injection of Placebo, by a weekly subcutaneous injection of two syringes on the same injection day, for 46 weeks.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Actual Maintenance Treatment

    Selected primary outcome

    Results · Nov 14, 2026 UTC

    Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Actual Maintenance Treatment

    Number · Percentage of participants · At baseline and at 48 weeks.

    Analysis population: Treated set - actual maintenance treatment. Patients are analyzed according to the actual treatment they received at the start of the dose maintenance period (for patients who reached the maintenance period) or the next maintenance dose up from the dose at treatment discontinuation (for patients who discontinued treatment prior to the maintenance period).

    Survodutide 2.4 mg - Actual Maintenance Treatment
    38.7 Percentage of participants (clinicaltrials.gov/study/NCT04771273)

    Overall outcome: 93 Participants (clinicaltrials.gov/study/NCT04771273) analyzed

    Survodutide 4.8 mg - Actual Maintenance Treatment
    63.8 Percentage of participants (clinicaltrials.gov/study/NCT04771273)

    Overall outcome: 69 Participants (clinicaltrials.gov/study/NCT04771273) analyzed

    Survodutide 6.0 mg - Actual Maintenance Treatment
    55.8 Percentage of participants (clinicaltrials.gov/study/NCT04771273)

    Overall outcome: 52 Participants (clinicaltrials.gov/study/NCT04771273) analyzed

    Placebo - Actual Maintenance Treatment
    15.2 Percentage of participants (clinicaltrials.gov/study/NCT04771273)

    Overall outcome: 79 Participants (clinicaltrials.gov/study/NCT04771273) analyzed

    Outcome definition & treatment groups

    Percentage of patients who had an improvement from baseline in liver histological findings based on liver biopsy after 48 weeks of treatment is reported. Percentages were rounded to one decimal place. Improvement in histological findings was defined as a composite of improvement in NASH and no worsening of fibrosis. Improvement in non-alcoholic steatohepatitis (NASH) was defined as decrease of at least 2 points in non-alcoholic fatty liver disease (NAFLD) activity score (NAS) with at least 1 point decrease in NAS subscore of either lobular inflammation or ballooning. The NAS represents the sum of subscores for steatosis (scored from 0-3), lobular inflammation (scored from 0-3) and ballooning (scored from 0-2), and the total score ranges from 0 to 8 with higher scores representing worsening of the disease. The total score for the fibrosis stage ranges from 0 to 4 with higher score indication worsening of the disease. Patients without post-baseline data were considered non-responders.

    Survodutide 2.4 mg - Actual Maintenance Treatment: This arm includes patients who were treated with 2.4 mg of survodutide administered weekly at the start of the maintenance period, for patients who reached the maintenance period, regardless of whether this was the randomised (planned) dose or not, and regardless of whether the patient stayed on that dose throughout the maintenance period. This arm includes also those patients for whom the next maintenance dose up from the dose at treatment discontinuation was 2.4 mg of survodutide administered weekly, for patients who discontinued treatment prior to the maintenance period, regardless of the reason for the treatment discontinuation.

    Survodutide 4.8 mg - Actual Maintenance Treatment: This arm includes patients who were treated with 4.8 mg of survodutide administered weekly at the start of the maintenance period, for patients who reached the maintenance period, regardless of whether this was the randomised (planned) dose or not, and regardless of whether the patient stayed on that dose throughout the maintenance period. This arm includes also those patients for whom the next maintenance dose up from the dose at treatment discontinuation was 4.8 mg of survodutide administered weekly, for patients who discontinued treatment prior to the maintenance period, regardless of the reason for the treatment discontinuation.

    Survodutide 6.0 mg - Actual Maintenance Treatment: This arm includes patients who were treated with 6.0 mg of survodutide administered weekly at the start of the maintenance period, for patients who reached the maintenance period, regardless of whether this was the randomised (planned) dose or not, and regardless of whether the patient stayed on that dose throughout the maintenance period. This arm includes also those patients for whom the next maintenance dose up from the dose at treatment discontinuation was 6.0 mg of survodutide administered weekly, for patients who discontinued treatment prior to the maintenance period, regardless of the reason for the treatment discontinuation.

    Placebo - Actual Maintenance Treatment: This arm includes patients who were treated with placebo matching survodutide administered weekly at the start of the maintenance period, for patients who reached the maintenance period, regardless of whether this was the randomised (planned) dose or not, and regardless of whether the patient stayed on that dose throughout the maintenance period. This arm includes also those patients who were receiving Placebo matching survodutide administered weekly and who discontinued treatment prior to the maintenance period, regardless of the reason for the treatment discontinuation.

    One of 2 registered primary outcomes, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™… (clinicaltrials.gov/study/NCT06077864)
    NCT06077864PHASE3Completed5,530 enrolled
  • LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced… (clinicaltrials.gov/study/NCT06632444)
    NCT06632444PHASE3Recruiting1,800 enrolled
  • LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis (clinicaltrials.gov/study/NCT06632457)
    NCT06632457PHASE3Recruiting1,590 enrolled
  • A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose… (clinicaltrials.gov/study/NCT06066528)
    NCT06066528PHASE3Completed755 enrolled
  • A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose… (clinicaltrials.gov/study/NCT06066515)
    NCT06066515PHASE3Completed726 enrolled
  • A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar (clinicaltrials.gov/study/NCT07754461)
    NCT07754461PHASE3Recruiting600 enrolled
  • SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going… (clinicaltrials.gov/study/NCT07850050)
    NCT07850050PHASE3Not_yet_recruiting600 enrolled
  • ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or… (clinicaltrials.gov/study/NCT07850063)
    NCT07850063PHASE3Not_yet_recruiting600 enrolled
  • A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight (clinicaltrials.gov/study/NCT06214741)
    NCT06214741PHASE3Completed307 enrolled
  • A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease (clinicaltrials.gov/study/NCT06176365)
    NCT06176365PHASE3Completed274 enrolled

Source: ClinicalTrials.gov API v2 (clinicaltrials.gov/search) · as of Nov 17, 2026

All trials on ClinicalTrials.gov (clinicaltrials.gov)
Related

Related GLP-1s to compare

Updated automatically

What changed for Survodutide

  • TrialNew Survodutide study registered: A Study to Compare How Survodutide is Taken up by the Body When Given in 2 Formulations to People With Overweight or Obesity (clinicaltrials.gov/study/NCT07940244)
  • StudyRandomized trial in Lancet: Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial (pubmed.ncbi.nlm.nih.gov/43003106)
  • StudyRandomized trial in Nat Med: Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial (pubmed.ncbi.nlm.nih.gov/42642663)
  • TrialNew Survodutide study registered: ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease (clinicaltrials.gov/study/NCT07850063)
  • TrialNew Survodutide study registered: SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight (clinicaltrials.gov/study/NCT07850050)

Written from each source's own record as it changes. Every change on GLPcompare

Not legally for sale

FDA's warning letters naming Survodutide

2 letters to companies selling it. Nobody can legally sell Survodutide today.

  • NuScience Peptides LLC (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026)Aug 24, 2026
  • Xcel Research LLC (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/xcel-research-llc-694608-12102024)Dec 10, 2024

Every FDA warning letter on GLP-1 sellers

ClinicalTrials.gov

What Survodutide is studied for

Registered trials of this medicine by condition. A trial shows a question being asked, not that the answer is yes.

From PubMed

Latest Survodutide trials and reviews

  • Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial (pubmed.ncbi.nlm.nih.gov/43003106)

    Randomized trial · Lancet · Nov 9, 2026 · Bozkurt B et al.

  • Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial (pubmed.ncbi.nlm.nih.gov/42642663)

    Randomized trial · Nat Med · Oct 1, 2026 · Kaplan LM et al.

  • Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN) (pubmed.ncbi.nlm.nih.gov/42599381)

    Randomized trial · Diabetes Ther · Aug 14, 2026 · Ji L et al.

  • Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity (pubmed.ncbi.nlm.nih.gov/42331726)

    Randomized trial · Diabetes Obes Metab · Jun 22, 2026 · Ekinci EI et al. · cited by 1

  • Survodutide Once Weekly for the Treatment of Adults with Obesity (pubmed.ncbi.nlm.nih.gov/42253238)

    Randomized trial · N Engl J Med · Jun 7, 2026 · le Roux CW et al. · cited by 14

  • Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial (pubmed.ncbi.nlm.nih.gov/42252333)

    Randomized trial · Nat Med · Jun 7, 2026 · Kaplan LM et al. · cited by 12

  • Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes (pubmed.ncbi.nlm.nih.gov/41216778)

    Randomized trial · Diabetes Obes Metab · Nov 11, 2025 · Wharton S et al. · cited by 5

  • Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1) (pubmed.ncbi.nlm.nih.gov/41187967)

    Randomized trial · Diabetes Obes Metab · Nov 4, 2025 · le Roux CW et al. · cited by 5

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Questions

Common questions about Survodutide

How much weight can you lose on Survodutide?
In its pivotal trial (SYNCHRONIZE-1 (Phase 3)), Survodutide at 6.0 mg weekly (Phase 3) showed a mean body-weight change of -16.6% at 76 wks. This is a trial average; individual results vary. Source (nejm.org)
Is Survodutide available yet?
No. Survodutide is investigational (Phase 3) and not FDA-approved, so it cannot be prescribed or bought yet.
When will Survodutide be FDA approved?
FDA has not approved Survodutide, and no public record gives an approval date. It is at this stage: Phase 3. The trial registry lists 11 Phase 3 trials: 6 finished and 5 still running. The sponsor lists the last of those as finishing by December 2031, though a company can file with FDA before every trial ends. Source
Can you buy Survodutide?
Not legally: FDA has not approved it, so no pharmacy can fill it. FDA has warned companies selling unapproved GLP-1 drugs labeled for research, and says: "The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health." FDA's warning letters naming it: 2 from Dec 10, 2024 to Aug 24, 2026. Source (fda.gov)
How much does Survodutide cost?
It has no legal price, because it is not approved and nobody can legally sell it. Prices online are for unapproved products of unknown quality. What approved GLP-1s cost is on our price pages. Source
Does insurance cover Survodutide?
No. It is not FDA approved, so it is on no plan's list, and an HSA or FSA has nothing legal to pay for. Coverage could only come after an approval. Source
Is there a generic Survodutide?
No. It has no approved brand to copy. Anything sold as a generic of it is an unapproved product. Source
What is the Survodutide dose?
There is no approved dose, because it has no FDA label. The result we cite was at 6.0 mg weekly (Phase 3). We do not publish dosing, units or mixing charts for an unapproved medicine: those charts online describe products FDA warns against.
How does Survodutide work?
An investigational dual glucagon/GLP-1 receptor agonist; the glucagon component is being studied for effects on liver fat and metabolism.
Is Survodutide a GLP-1?
Dual glucagon and GLP-1 receptor agonist. Source
Who makes Survodutide?
Boehringer Ingelheim / Zealand Pharma.
Can you join a Survodutide trial?
A clinical trial is one legal way to receive a medicine FDA has not approved. ClinicalTrials.gov shows 3 trials recruiting now, with who can enroll and where. Source (clinicaltrials.gov)
What are the side effects of Survodutide?
GI events (nausea 65%, vomiting 45%, diarrhea 40%) affected 89.7% of the 6.0 mg arm, the highest GI burden of the class, mostly mild-to-moderate and during dose escalation. Stopped because of side effects: 24.8% vs 5.4% placebo (6.0 mg). From SYNCHRONIZE-1 (6.0 mg, 76 wks, obesity). These come from trials, not a label. Source (nejm.org)